DarioHealth Corp. (NASDAQ:DRIO ) Q4 2024 Earnings Conference Call March 10, 2025 8:30 AM ET Company Participants Kat Parrella - Investor Relations Manager Erez Raphael - Chief Executive Officer Steven Nelson - Chief Commercial Officer Conference Call Participants Charles Rhyee - TD Cowen Ashok Kumar - ThinkEquity David Grossman - Stifel Operator Good morning, ladies and gentlemen, and welcome to the DarioHealth Fourth Quarter 2024 Results Conference Call. At this time, all lines are in listen-only mode.
NEW YORK--(BUSINESS WIRE)---- $DRIO #Biotech--Market News Alerts Updates: Market News Alerts Reports: DarioHealth Corp. (Nasdaq: DRIO) reported fourth quarter revenue of $7.6 million, beating analyst consensus of $7.39 million. B2B2C recurring revenue surged 398% year-over-year to $5.6 million in Q4, driven by rapid employer and health plan adoption of the company's comprehensive chronic care platform. Gross margins in the B2B2C business exceeded 80% over the past three quarters. Full-year 2024 revenue reached $2.
Full-year 2024 revenue increased by 32.9% to $27.0 million from $20.4 million revenue in 2023. Revenue growth driven by B2B2C channel including employers and health plans resulting in recurring revenues which increased by 300% year over year as core business continues to gain traction.
The strategic arrangement fuels Dario's B2B2C sales growth, expanding access to over 15,000 providers nationwide NEW YORK , March 7, 2025 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, today announced a strategic collaboration with Rula Health, a leading provider of high-quality behavioral health services, to expand access to mental health support for employers and their workforce nationwide. Through this strategic collaboration, Dario clients will have access to Rula's extensive network of over 15,000 providers across the country with coverage of over 120 million commercial lives through most major insurance networks.
Healthcare system collaborates with Dario to offer AI-powered chronic care management solutions as a benefit for their employee base of healthcare workers, expected to contribute to the current total of 15 new client signings in 2025, representing a significant head start in its 2025 net new client goal. NEW YORK , March 5, 2025 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced today the signing of a contract with a major healthcare system to be added to its employer book of business, set to go live in the first quarter of 2025.
Company to host conference call and webcast at 8:30am Eastern Time NEW YORK , March 4, 2025 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced today that it will release its financial results for the 4th quarter ended December 31 st, 2024 and will host a conference call and webcast at 8:30 am Eastern Time, on Monday, March 10 th, 2025, before the market opens. Erez Raphael, Chief Executive Officer, and Steven Nelson, Chief Commercial Officer, will host the call.
NEW YORK--(BUSINESS WIRE)---- $DRIO #AI--Market News Alerts Updates: DarioHealth Corp. (Nasdaq: DRIO)* has announced a significant new agreement with a Blue Cross Blue Shield (BCBS) health plan, marking a pivotal expansion in the fast-growing digital health landscape. This move integrates Dario's AI-driven cardiometabolic digital health solutions, covering diabetes, hypertension, and weight management, into the offerings of one of America's most trusted health insurers. According to a recent report, the card.
NEW YORK--(BUSINESS WIRE)---- $DRIO #GLP1--PESG Releases Report: In a healthcare market brimming with potential, DarioHealth Corp. (Nasdaq: DRIO)* is quietly emerging as a standout player, combining cutting-edge technology with proven outcomes. Looking at recent achievements, it seems DarioHealth's multi-condition digital health platform and its accelerating financial trajectory may position it as a sleeper hit in a rapidly growing sector. Breaking Down the Opportunity At the heart of DarioHealth's success is.
Significant participation from existing shareholders and accredited healthcare investors, which the company believes underscores confidence in its strategy Financing supports execution of long-term growth initiatives focused on high-margin, scalable recurring revenues across B2B (Business-to-Business) and pharma channels NEW YORK , Jan. 21, 2025 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a prominent leader in the global digital health industry, announced today the successful closing of a $25.6 million private placement of convertible preferred stock, priced in accordance with Nasdaq market rules. The majority of the funds were secured from existing shareholders, with the remainder contributed by a network of leading accredited healthcare investors and executives from the healthcare sector.
New collaboration enhances Dario's comprehensive GLP-1 offering with virtual physician management to meet growing demand from employers covering weight-loss medications, opening new revenue streams in direct-to-consumer and pharma channels NEW YORK , Jan. 14, 2025 /PRNewswire/ -- January 14, 2025 -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, today announced a collaboration with MediOrbis, a multi-specialty digital health provider, to add prescribing capabilities to Dario's GLP-1 behavior change solution for a comprehensive medical weight loss program. This strategic addition creates a fully integrated solution for employers covering weight-loss medications and supports direct-to-consumer offerings, expanding Dario's addressable market in one of the fastest-growing segments of digital health.